[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20230200A - Moduladores del regulador de la conductancia transmembrana de la fibrosis quística - Google Patents

Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Info

Publication number
CR20230200A
CR20230200A CR20230200A CR20230200A CR20230200A CR 20230200 A CR20230200 A CR 20230200A CR 20230200 A CR20230200 A CR 20230200A CR 20230200 A CR20230200 A CR 20230200A CR 20230200 A CR20230200 A CR 20230200A
Authority
CR
Costa Rica
Prior art keywords
modulators
cystic fibrosis
conductance regulator
transmembrane conductance
fibrosis transmembrane
Prior art date
Application number
CR20230200A
Other languages
English (en)
Inventor
Sunny Abraham
Corey Don Anderson
Vijayalaksmi Arumugam
Timothy A Dwight
Anton V Gulevich
Jaclyn Chau
Ruah Sara Sabina Hadida
Vito Melillo
Jeremy Clemens
Paul Krenitsky
Lino Valdez
Jinglan Zhou
Jason Mccartney
Prasuna Paraselli
Thomas Cleveland
Mark Thomas Miller
Peter Grootenhuis
Alexander Russell Abela
Joe A Tran
Haripada Khatuya
Bryan A Frieman
Yoshihiro Ishihara
Alina Silina
Johnny Uy
Lev Tyler Dewey Fanning
Timothy Richard Coon
Fabrice Pierre
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20230200A publication Critical patent/CR20230200A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción proporciona moduladores del regulador de la conductancia transmembrana de la fibrosis quística (CFTR) que tiene la estructura central: composiciones farmacéuticas que contienen al menos un modulador de este tipo, métodos de tratamiento de enfermedades mediadas por CFTR, que incluyen fibrosis quística, mediante el uso de tales moduladores y composiciones farmacéuticas, composiciones farmacéuticas combinadas y terapias combinadas, y procesos y productos intermediarios para la fabricación de tales moduladores.
CR20230200A 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística CR20230200A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088935P 2020-10-07 2020-10-07
PCT/US2021/053860 WO2022076624A1 (en) 2020-10-07 2021-10-06 Modulators of cystic fibrosis transmembrane conductance regulator

Publications (1)

Publication Number Publication Date
CR20230200A true CR20230200A (es) 2023-07-13

Family

ID=78771139

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230200A CR20230200A (es) 2020-10-07 2021-10-06 Moduladores del regulador de la conductancia transmembrana de la fibrosis quística

Country Status (20)

Country Link
US (1) US20230382925A1 (es)
EP (1) EP4225764A1 (es)
JP (1) JP2023545081A (es)
KR (1) KR20230104618A (es)
CN (1) CN116783204A (es)
AR (1) AR123709A1 (es)
AU (1) AU2021358063A1 (es)
BR (1) BR112023006381A2 (es)
CA (1) CA3197857A1 (es)
CL (1) CL2023000984A1 (es)
CO (1) CO2023005734A2 (es)
CR (1) CR20230200A (es)
DO (1) DOP2023000066A (es)
EC (1) ECSP23032164A (es)
IL (1) IL301755A (es)
MX (1) MX2023004074A (es)
PE (1) PE20231185A1 (es)
TW (1) TW202233635A (es)
UY (1) UY39460A (es)
WO (1) WO2022076624A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharma PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
WO2023150237A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2023249173A1 (en) * 2022-04-06 2024-10-03 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202421102A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
WO2024056779A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
EP2404919B1 (en) 2005-11-08 2013-08-21 Vertex Pharmaceuticals Incorporated Heterocyclic compound useful as a modulator of ATP-binding cassette transporters.
US20110064811A1 (en) 2005-12-28 2011-03-17 Patricia Hurter Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
EP2021797B1 (en) 2006-05-12 2011-11-23 Vertex Pharmaceuticals, Inc. Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide
SI2225230T1 (sl) 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
BRPI0820902A2 (pt) 2007-12-07 2015-06-23 Vertex Pharmaceuticals Incorporarted Processo para produção de ácidos benzoicos de cicloalquilcarboxamidopiridina
HUE035931T2 (hu) 2008-08-13 2018-06-28 Vertex Pharma N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása
BRPI0919550A2 (pt) 2008-09-29 2019-09-10 Vertex Pharma unidades de dosagem de ácido 3-(6-(1-(2,2-difluorobenzo]d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
CN102272127A (zh) 2008-11-06 2011-12-07 弗特克斯药品有限公司 Atp-结合盒转运蛋白调节剂
SG193156A1 (en) 2009-03-20 2013-09-30 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
RU2711481C2 (ru) 2010-03-25 2020-01-17 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА
US9504623B2 (en) 2010-04-09 2016-11-29 Ekso Bionics, Inc. Exoskeleton load handling system and method of use
US9035072B2 (en) 2010-04-22 2015-05-19 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
WO2011133951A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
JP2013536251A (ja) 2010-08-27 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド 薬学的組成物およびその投与
CA2834574C (en) 2011-05-18 2019-09-17 Concert Pharmaceuticals Inc. Deuterated derivatives of ivacaftor
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
BR112015009913B1 (pt) 2012-11-02 2023-04-11 Vertex Pharmaceuticals Incorporated Comprimido compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo, seu processo de preparação, kit e método de preparação de um grânulo compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo
MY178621A (en) 2012-11-19 2020-10-19 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
LT3925607T (lt) 2014-04-15 2023-11-27 Vertex Pharmaceuticals Incorporated Farmacinė kompozicija, skirta gydyti ligas, kurias nulemia cistinės fibrozės transmembraninio laidumo reguliatorius
BR112018005454A2 (pt) 2015-09-21 2018-10-09 Vertex Pharmaceuticals Europe Ltd administração de potencializadores de cftr deuterados
WO2018080591A1 (en) 2016-10-27 2018-05-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated cftr potentiators
SI3752510T1 (sl) * 2018-02-15 2023-03-31 Vertex Pharmaceuticals Incorporated Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo
AR118555A1 (es) * 2019-04-03 2021-10-20 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP4013760A1 (en) * 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators

Also Published As

Publication number Publication date
UY39460A (es) 2022-05-31
CL2023000984A1 (es) 2023-11-24
CA3197857A1 (en) 2022-04-14
AU2021358063A1 (en) 2023-05-18
TW202233635A (zh) 2022-09-01
KR20230104618A (ko) 2023-07-10
DOP2023000066A (es) 2023-07-09
WO2022076624A1 (en) 2022-04-14
MX2023004074A (es) 2023-07-05
IL301755A (en) 2023-05-01
US20230382925A1 (en) 2023-11-30
EP4225764A1 (en) 2023-08-16
AR123709A1 (es) 2023-01-04
PE20231185A1 (es) 2023-08-11
JP2023545081A (ja) 2023-10-26
BR112023006381A2 (pt) 2023-09-26
CN116783204A (zh) 2023-09-19
CO2023005734A2 (es) 2023-07-21
ECSP23032164A (es) 2023-06-30

Similar Documents

Publication Publication Date Title
ECSP23032164A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CO2023005736A2 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CO2022002749A2 (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quística
ECSP23032843A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39723A (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
UY39455A (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123707A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123706A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123711A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
BR112021019102A2 (pt) Composições e métodos para tratamento de fibrose cística
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
CO2024013546A2 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
BR112016029926A2 (pt) administração nasal
ECSP20082568A (es) Métodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropión
AR129032A1 (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39521A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
UY39603A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
AR113249A1 (es) Microorganismos para uso y entrega al sistema respiratorio